Peter Russell

Jeff Bezos’ Blue Origin aims to fly first passengers on its space tourism rocket as early as April

Jeff Bezos’ space company Blue Origin on Thursday completed the fourteenth test flight of its New Shepard rocket booster and capsule.
CNBC has learned that NS-14 also marked one of the last remaining steps before Blue Origin flies its first crew to space, with Thursday’s flight the first of two “stable configuration” tests.
Blue Origin aims to launch the second test flight within six weeks, or by late February, and the first crewed flight six weeks after that, or by early April, people familiar with the company’s plans told CNBC.

Biden’s $1.9 trillion Covid relief plan calls for stimulus checks, unemployment support and more

President-elect Joe Biden on Thursday unveiled the details of a $1.9 trillion coronavirus rescue package.
The proposal, titled the American Rescue Plan, includes familiar stimulus measures with the goal of sustaining families and firms until vaccines are widely distributed.
The current plan is the first of two major spending initiatives Biden will seek in the first few months of his presidency.

Crypto investment firm Grayscale sees 900% jump in assets to $20 billion amid bitcoin frenzy

Grayscale kicked off last year with $2 billion in assets under management and ended with more than $20.2 billion, driven by demand from institutional investors such as hedge funds, endowments and pension funds.
Grayscale’s Bitcoin Trust became a popular, publicly traded way for investors to get exposure to cryptocurrency without owning the coins themselves.
“There’s no longer professional risk of investing in the digital currency asset class — there’s probably more career risk in not paying attention to it,” said CEO Michael Sonnenshein.

China gives conditional approval to Sinopharm coronavirus vaccine

The vaccine is the first one approved for general use in China.
The vaccine is an inactivated, two-dose vaccine from the Beijing Institute of Biological Products, a subsidiary of state-owned conglomerate Sinopharm.
The company announced Wednesday that preliminary data from last-stage trials had shown it to be 79.3% effective.

China’s IPO market is set to keep booming in 2021, says investor

Noah Holdings’ William Ma expects the demand for IPOs in China to remain high next year, following a “very exciting” 2020.
Stock listings of Chinese firms have dominated the global rankings in 2020, according to research from EY.
Among the top 10 listings globally, Chinese firms made up half of the list while also taking the top three spots.